Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.
Investor's Business Daily on MSN
Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival Bayer
Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock ...
Stocktwits on MSN
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt
Bayer said its new Phase III stroke study of asundexian hit both primary efficacy and safety goals. ・The update comes two ...
German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a ...
I am struggling with a decision process due to a lack of consensus among various physicians. I was fortunate back in January ...
Texas Attorney General Ken Paxton claims that for decades the drugmakers failed to disclose that the medication is less effective in some minority patients, but the companies say the lawsuit is "stale ...
Several large studies have been unable to find any reduction in the already low risk of developing a prosthetic joint ...
Dear Dr. Roach: I am struggling with a decision process due to a lack of consensus among various physicians. I was fortunate ...
Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi on Thursday, accusing the drugmakers of failing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback